Clinical Remission among Severe Asthmatics on Monoclonal Antibody Therapy: Real-World Outcomes at 2 Years.
ERJ open research(2024)
摘要
Real-world data suggest clinical remission is a feasible treatment goal of monoclonal antibody therapy. Evidence of ongoing response post-12 months may be used to inform treatment decisions. Further work is needed to standardise criteria for remission. https://bit.ly/4cA6TkG.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn